Dianthus therapeutics announces inducement grants under nasdaq listing rule 5635(c)(4)

New york and waltham, mass., may 03, 2024 (globe newswire) -- dianthus therapeutics, inc. (“dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on may 1, 2024, to two newly-hired, non-executive employees. the inducement grants were approved by the company's independent compensation committee and were made as material inducements to acceptance of employment with dianthus in accordance with nasdaq listing rule 5635(c)(4).
DNTH Ratings Summary
Quant
DNTH Quant Ranking
Sector
Industry
Quant Rating
Quant Score